Brief: Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector
01/12/2025 13:05
Dec 1 (Reuters) - MannKind Corp MNKD.O: MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN ADULTS WITH CHRONIC HEART FAILURE OR CHRONIC KIDNEY DISEASE MANNKIND CORP - PDUFA TARGET ACTION DATE SET FOR JULY 26, 2026 Source text: ID:nGNX9rqQK6 Further company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children